Patient Specific Guides and Surgical Planning for Periacetabular Osteotomy; Post Marketing Evaluation Study (MyPAO)
MyPAO Patient Specific Guides and Surgical Planning for Periacetabular Osteotomy; Post Marketing Evaluation Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Birmingham, United Kingdom
- Recruiting
- The Royal Orthopaedic Hospital NHS Trust
-
Contact:
- Gareth Mr Stephens, BSc
- Phone Number: 01216854316
- Email: gareth.stephens@nhs.net
-
Contact:
- sam papadopoullos, BSc
- Phone Number: 01216854316
- Email: sam.papadopoullos@nhs.net
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
· Age greater than 18 years
- Patient undergoing pelvic osteotomy
Exclusion Criteria:
· Evidence of hip degeneration assessed by the surgeon on x-ray (Tonnis Grade 1 or greater)
- Known allergy to Polyamide PA12
- Unable to provide written informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: MyPAO use
SIngle arm study, use of device
|
use of MyPAO surgical guide to support periacetabular osteotomy procedures for treatment of acetabular dysplasia
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Product safety assessment
Time Frame: 3 months post-surgery
|
evaluate the use of the MyPAOTM technology by reviewing number of device related adverse events, in order to continue to assess product safety as part of post marketing surveillance.
|
3 months post-surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proof of concept
Time Frame: 12 months
|
surgeon questionnaires after each case.
We will determine technical difficulties in using the device, surgeon satisfaction with the use of guides and the guided correction and the presence of any intra-operative adverse events.
|
12 months
|
|
i-hot12 questionnaire
Time Frame: 12 months post-surgery
|
hip-specific health related quality of life outcome tool
|
12 months post-surgery
|
|
Eq-5D
Time Frame: 12 months post-surgery
|
validated measure of health-related quality of life
|
12 months post-surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ROH22ORTH13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.